RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
ESR 1 promoter hypermethylation does not predict atypia in random periareolar fine needle aspiration nor persistent atypia after 12 months tamoxifen chemoprevention
Seewaldt, V., Baker, J., Bean, G., Lem, S., Goldenberg, V., Rowell, C., Iharra-Drendall, C., Ostrander, J., Grant, T., Pilie, P., Vasilatos, S., Troch, M., Scott, V., Wilke, L., Paisie, C., Rahiner, S., Tores, A., Zalles, C., & Broadwater, G. (2008). ESR 1 promoter hypermethylation does not predict atypia in random periareolar fine needle aspiration nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiology, Biomarkers and Prevention, 17(8), 1884 - 1890.